RNA Targeted Therapeutics Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
RNA Targeted Therapeutics Market is Segmented By Type of Target Molecule (Cap Binding Complex, CDKL5, Dystrophin Protein, Erα, G542X, MNK1 / MNK2, PAX6 gene, SMN2), By Type of Approach (Indirect RNA Targeting: Epitranscriptomics, mRNA Translation Modulation, RNA Splicing Modification), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
RNA Targeted Therapeutics Market Size
Market Size in USD
CAGR35.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 35.2% |
| Market Concentration | High |
| Major Players | Abivax, AC Immune, Arrakis Therapeutics, eFFECTOR Therapeutics, Eloxx Pharmaceuticals |
please let us know !
RNA Targeted Therapeutics Market Analysis
The RNA targeted therapeutics market is estimated to be valued at USD 1.34 Bn in 2024 and is expected to reach USD 11.2 Bn by 2031, growing at a compound annual growth rate (CAGR) of 35.2% from 2024 to 2031.
The market is witnessing positive trends owing to rising prevalence of target medical conditions and increasing number of RNA therapeutics under clinical trials. There has been a considerable increase in research and development activities for RNA therapeutics over the past decade. Many biopharma companies are actively working on RNA interference technologies to develop treatment for cancer, genetic diseases, and infectious diseases. Recent regulatory approvals and successful commercialization of few RNA therapeutics have boosted confidence in this platform. If upcoming clinical trial results are positive, it may lead to approval and commercialization of more RNA drugs in the near future. This will upsurge demand and drive higher market revenues during the forecast period.